Drugs / VRB-101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07628127 | Jul 2026 → Mar 2028 expected | obesity disorder | Verdiva Bio Dev Limited | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07553299 | Jun → Nov 2026 expected | obesity disorder | Verdiva Bio Dev Limited | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07281937 | Nov 2025 → Jul 2026 overdue | obesity disorder | Verdiva Bio Dev Limited | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-06-21 | Verdiva Bio Dev Limited | Results Verdiva Bio to present new data highlighting once-weekly potential of its investigational oral obesity candidates at the ADA 85th Scientific Sessions verdivabio.com ↗
Phase 1 data evaluating VRB-101, Verdiva Bio’s, cAMP-biased oral GLP-1RA, provides proof of concept for potential once-weekly oral administration. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-24 | Verdiva Bio Dev Limited | Verdiva Bio Announces Completion of Enrollment for EVOLVE-2 Phase 2b Study of VRB-101, a potential Once-Weekly Oral GLP-1 Peptide Analog in Individuals with Obesity verdivabio.com ↗ |
| 2025-06-21 | Verdiva Bio Dev Limited | Verdiva Bio to present new data highlighting once-weekly potential of its investigational oral obesity candidates at the ADA 85th Scientific Sessions verdivabio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRB-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07281937 ↗ |
| Route | Oral | “VRB-101 tablets will be administered orally.” NCT07281937 ↗ |